<DOC>
	<DOCNO>NCT01195857</DOCNO>
	<brief_summary>Multiple sclerosis ( MS ) chronic , inflammatory , demyelinate disease central nervous system ( CNS ) one common cause neurological disability young adult . Rebif license United Kingdom treatment relapse MS give 3 time per week subcutaneous injection . The Rebiject II device autoinjector allow patient easy administration Rebif injection . Prior treatment , patient receive training use device maintenance . Currently , treatment MS injectable require long term patient commitment . Rebiject develop improve patient convenience comfort require multiple step carry order injection deliver correctly . Reports local call centre nurse advisor suggest inaccuracy use Rebiject device common . By raise awareness level inaccuracy determine step patient likely complete correctly , modify training program modification current subject training may put place address issue . It also important demonstrate link poor use medication device increase relapse rate increase injection site reaction .</brief_summary>
	<brief_title>Assessment Subject Use Rebiject II Injection Device According Nurse Examination Subject Accuracy 10 Steps Dummy Demonstration</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Have relapse remit multiple sclerosis currently receive Rebif treatment use Rebiject II injection device Be regular review MS nurse Be age 18 Be willing able participate trial provide write informed consent Receiving disease modify therapy Rebif Receiving Rebif use Rebiject II injection device Do self inject Are unable unwilling provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Rebif</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>